NuvaRing DTC leads web traffic

Share this article:
NuvaRing and Latisse lead the pack in DTC-driven traffic to their brand.com sites, according to Manhattan Research.

The research firm's ePharma Consumer survey found that Merck Contraceptive NuvaRing jumped five spots to take the top spot for ad-driven traffic, while Allergan's eyelash-extender, Latisse, launched last year, placed second. Sexual health products dominated the top 10. Latisse was followed by Cialis, Boniva, Abilify, Gardasil, Yaz, Viagra, Levitra and Lunesta.

“These are things where talking to friends and family or doctors might be awkward, so they want to research it on their own,” said VP of research Meredith Ressi.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets